A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Mayo Clinic Hospital, Scottsdale, Arizona +144 locations
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
Early Genomic Testing for Inherited Bleeding Disorders
NCT06736158
Recruiting
The investigators aim to test the introduction of genomic testing early in the diagnostic pathway for inherited bleeding disorders in patients who have not received a diagnosis after first-line testing. The goal of this clinical trial is to test the introduction of genomic testing early in the diagnostic pathway for patients referred to Hematology for a suspected inherited bleeding disorder. The main questions it aims to answer are: 1. Does adding early genomic testing increase the number of p... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Queen's University/Kingston Health Sciences Centre, Kingston, Ontario +2 locations
Conditions: Bleeding Disorder
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/28/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona +179 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism
NCT06393868
Recruiting
The investigators are studying whether treatment with a proton pump inhibitor called omeprazole reduces gastrointestinal bleeding in older adults taking blood thinners for a blood clot (venous thromboembolism). The purpose of this study, a pilot study or a feasibility study, is to test the study plan and determine whether enough participants will join a larger study and accept the study procedures.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/28/2025
Locations: The Ottawa Hospital, Ottawa, Ontario +2 locations
Conditions: Venous Thromboembolism, Gastro Intestinal Bleeding, Blood Clot
Register for Updates
Imaging of Vitreous Opacities in a Canadian Population
NCT06204848
Recruiting
The goal of this clinical trial is to capture imaging data of eye floaters in the population to build an imaging database to learn more about them in. Participants will imaged with an investigational ophthalmic imaging device to capture images of their floaters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Alberta Retina Consultants, Edmonton, Alberta
Conditions: Floaters, Vitreous Opacities
Register for Updates
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245
Recruiting
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Clinical Research Advisors, LLC, Beverly Hills, California +204 locations
Conditions: Patients With Non-Small Cell Lung Cancer
Register for Updates
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Little Rock, Arkansas +51 locations
Conditions: Hereditary Angioedema (HAE)
Register for Updates
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
NCT06602453
Recruiting
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/28/2025
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +30 locations
Conditions: Acute Kidney Injury
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama +278 locations
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial
NCT06884540
Recruiting
Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus), Québec, Quebec
Conditions: Anesthesia, Anesthesia Complication, Surgery, Quality of Life, Pain, Postoperative, Anesthesia Morbidity, Feasibility Studies, Patient-centredness
Register for Updates
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312
Recruiting
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
07/28/2025
Locations: Arizona Arthritis and Rheumatology Associates PLLC, Avondale, Arizona +108 locations
Conditions: Polymyalgia Rheumatica
Register for Updates
Pan-Canadian Lung Cancer Observational Study (PALEOS)
NCT04706754
Recruiting
A multicenter, ambispective observational study focusing on patients diagnosed with lung cancer in Canada identified after January 1, 2000 inclusive. This data will be combined with that from deceased patients identified.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Milena (Lynn) Vicente, Brampton, Ontario
Conditions: Lung Cancer
Register for Updates